Amgen Inc. vs Assurant, Inc.: Strategic Comparison

This in-depth comparison examines Amgen Inc. and Assurant, Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Amgen Inc. on its own, evaluating Assurant, Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Amgen Inc. and Assurant, Inc. is widest.

On the headline numbers, Amgen Inc. reports annual revenue of $36.8B against $12.8B for Assurant, Inc., while their respective market capitalizations stand at $228.2B and $13.0B. Both Amgen Inc. and Assurant, Inc. are headquartered in United States, so they compete in a shared home market and regulatory environment.

Amgen Inc.: Amgen is one of the companies that created the biotechnology industry. Instead of synthesizing small-molecule drugs, it engineers living cells to make complex proteins, an approach it first commercialized with Epogen in 1989. Based in Thousand Oaks, California, it is best known for medicines in bone health, inflammation, cardiovascular disease and kidney disease, and since the 2023 Horizon acquisition in rare disease. Fiscal 2025 revenue was US$36.8 billion across a portfolio in which 14 products each sold more than US$1 billion, although several of the older brands are now losing both price and volume.

Assurant, Inc.: Assurant is the company behind protection products other brands put their name on. The device protection plan a T-Mobile customer adds to a new phone, the extended service contract a retailer sells with an appliance, the vehicle service contract a dealer sells with a used car, the renters policy a property manager requires at lease signing, the homeowners policy a mortgage servicer places when a borrower lets coverage lapse: Assurant underwrites or administers those programs and handles the claims. It is a Fortune 500 company listed on the New York Stock Exchange as AIZ, headquartered in Atlanta and operating in 21 countries.

Amgen Inc. and Assurant, Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Amgen Inc. and Assurant, Inc..

Amgen Inc. business model: Amgen operates a high-risk, high-reward biopharmaceutical business model. It spends heavily on research to discover and engineer new biologic drugs: US$7.3 billion in fiscal 2025, or 20.7% of product sales. Once a drug is approved by the FDA, Amgen secures a patent, granting them a temporary monopoly to sell the drug at a premium price. Because biologic drugs are grown from living cells rather than chemically synthesized, they are much harder for competitors to copy, resulting in slightly longer and more defensible monopolies than traditional pills.

Assurant, Inc. business model: Assurant sells almost nothing under its own brand. It builds protection programs that partners distribute: T-Mobile's Protection 360 device plans, extended service contracts sold by retailers, vehicle service contracts sold through auto dealers, renters insurance offered through property managers, and lender-placed homeowners insurance bought by mortgage servicers when a borrower's own policy lapses. Assurant underwrites or administers the risk, prices it and runs the claim, which for mobile means receiving the broken handset, repairing or replacing it, and reselling the recovered device. Partners earn a share of the economics without holding the insurance risk. The 10-K calls this business-to-business-to-consumer distribution.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Amgen Inc. stack up against those of Assurant, Inc..

Amgen Inc. competitive advantage: Amgen's main competitive advantage is experience making complex biologics at commercial scale, which it has done continuously since Epogen launched in 1989. Producing a glycosylated protein or a monoclonal antibody to a consistent specification requires validated facilities, process know-how and a regulatory record that take years to build, which is also why the company can turn the same capability toward biosimilars of competitor products. Its balance sheet lets it buy late-stage assets rather than rely only on internal discovery: Onyx, Otezla, Five Prime, ChemoCentryx and Horizon together cost about US$57 billion between 2013 and 2023.

Assurant, Inc. competitive advantage: Assurant's advantage is physical and contractual rather than brand-led. It processes about 20 million devices a year through eight device care centers, including the Nashville Innovation and Device Care Center, which runs automated lines using robotics and AI, and it offers same-day, same-unit repairs through a network of roughly 1,150 repair and partner locations. That reverse-logistics capacity lets Assurant settle a claim with a refurbished handset and resell the damaged one, which a carrier cannot easily build and a cash-paying insurer cannot match on cost. On the housing side, the lender-placed program is integrated into servicer systems under mostly exclusive three-to-five-year agreements, which makes displacement slow.

Future prospects matter as much as current results. The growth strategies below explain how Amgen Inc. and Assurant, Inc. each plan to expand from here.

Amgen Inc. growth strategy: Amgen's growth plan has two parts: scale the newer medicines and buy what the pipeline does not supply. Recent launches and acquired products drove the 10% revenue growth in fiscal 2025, with Tezspire up 52% to US$1.48 billion, Repatha up 36% to US$3.02 billion, Evenity up 34% to US$2.10 billion, Uplizna up 73% to US$655 million and Imdelltra reaching US$627 million in its second year. The company is pushing into obesity with MariTide, now in six Phase 3 MARITIME studies, and runs a biosimilars business that produced about US$3.0 billion of fiscal 2025 sales across Pavblu, Mvasi, Amjevita and Wezlana.

Assurant, Inc. growth strategy: Growth comes from three places. First, more of the device lifecycle: mobile trade-in programs Assurant runs returned a record $6.4 billion to consumers in 2025, up 42% year over year, and the company handles roughly 22 million trade-ins annually, which supplies the certified pre-owned inventory it uses to settle claims. Second, geography and channel inside capabilities it already has, which is what the April 2024 purchase of UK repair chain iSmash, the October 2025 purchase of OptoFidelity's device test automation portfolio and the January 2026 purchase of RL Circular Operations in Australia and New Zealand were for. Third, lines adjacent to the housing book, most visibly Assurant Home Warranty, which launched in 2025 and is being funded through the Corporate and Other segment. Global Housing's own 2025 growth came from more lender-placed policies in force and higher average premiums rather than from new products.

A closer look at the financial trajectory of Amgen Inc. and Assurant, Inc. rounds out the comparison.

Amgen Inc.: Amgen is a cash-generative business with high product gross margins. In fiscal 2025 it reported US$36.8 billion of total revenues, US$7.7 billion of GAAP net income, a 25.8% GAAP operating margin, US$8.1 billion of free cash flow and US$5.1 billion of dividends paid. Its results used to depend on a few large franchises, first Epogen and Aranesp, then Enbrel. As those matured Amgen bought revenue instead: Onyx in 2013, Otezla in 2019 and Horizon Therapeutics for US$27.8 billion in 2023. That last deal is also the main reason for the balance sheet it now carries, with US$54.6 billion of debt outstanding at December 31, 2025, debt leverage of about 3.2 times EBITDA and US$2.8 billion of net interest expense in fiscal 2025.

Assurant, Inc.: Assurant's revenue is recurring and mostly billed by someone else, arriving as a line on a phone bill, a mortgage escrow payment or a dealer finance contract. FY2025 revenue was $12.81 billion, up 7.9% from $11.88 billion, and GAAP net income was $872.7 million, up 15% from $760.2 million. Net earned premiums, fees and other income from the two segments totaled $12.35 billion, up 8% from $11.42 billion. Adjusted EBITDA was $1,536.2 million, or $1,734.4 million excluding $198.2 million of reportable catastrophes. GAAP earnings were $16.93 per diluted share. The company closed 2025 with $36.29 billion of total assets, $10.06 billion of investments, $2.21 billion of debt at 27.3% of total capital and $887 million of holding company liquidity against a $225 million internal minimum. It returned $468 million to shareholders during the year, repurchasing 1.4 million shares for $300 million and paying $168 million of common stock dividends, with $745 million left under existing repurchase authorizations as of February 6, 2026.